Vancouver, British Columbia / TheNewswire / March 12, 2019 - BioMark Diagnostics Inc. ("BioMark") (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled "DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES" has been granted in China on February 15, 2019.
Rashid Ahmed, President and CEO, says, "Granting of this patent expands and strengthens our metabolite measurement capabilities by offering options to cost effectively and reliably quantify the substrate of interest (acetylamantadine) in a biological sample for our SSAT1 urine-based assay using Raman spectroscopy. This technology can be used in economically and resource challenged environments on a global basis once the SSAT1 assay is approved by regulators".
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved or disapproved the content of this press release.